Singapore markets close in 2 hours 37 minutes

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.35-0.02 (-0.27%)
At close: 04:00PM EDT
7.38 +0.03 (+0.41%)
After hours: 07:55PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.39B
Enterprise value 1.81B
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)4.50
Price/book (mrq)56.59
Enterprise value/revenue 5.90
Enterprise value/EBITDA -13.86

Trading information

Stock price history

Beta (5Y monthly) 1.88
52-week change 3-43.07%
S&P500 52-week change 314.91%
52-week high 314.50
52-week low 36.62
50-day moving average 37.19
200-day moving average 38.50

Share statistics

Avg vol (3-month) 32.53M
Avg vol (10-day) 33.06M
Shares outstanding 5189.49M
Implied shares outstanding 6189.49M
Float 8158.74M
% held by insiders 11.24%
% held by institutions 193.70%
Shares short (14 Sept 2023) 442.5M
Short ratio (14 Sept 2023) 418.41
Short % of float (14 Sept 2023) 425.19%
Short % of shares outstanding (14 Sept 2023) 422.43%
Shares short (prior month 14 Aug 2023) 440.06M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Jun 2023


Profit margin -79.15%
Operating margin (ttm)-36.81%

Management effectiveness

Return on assets (ttm)-13.56%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)306.64M
Revenue per share (ttm)1.63
Quarterly revenue growth (yoy)25.90%
Gross profit (ttm)10.94M
EBITDA -111.28M
Net income avi to common (ttm)-242.72M
Diluted EPS (ttm)-1.29
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)410.67M
Total cash per share (mrq)2.17
Total debt (mrq)827.63M
Total debt/equity (mrq)N/A
Current ratio (mrq)5.47
Book value per share (mrq)-2.05

Cash flow statement

Operating cash flow (ttm)-122.62M
Levered free cash flow (ttm)-110.72M